Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CompleGen, a drug discovery company, has delivered its XenoGene technology to Boehringer Ingelheim as part of a non-exclusive agreement.
Subscribe to our email newsletter
Boehringer’s discovery team will apply the drug discovery technology to explore targets that are not easily accessible by other discovery platforms.
The XenoGene technology is said to use the power of genetics to identify allosteric inhibitors that are selective for specific protein targets.
CompleGen with a small molecule library, has identified potent allosteric inhibitors for targets where other discovery platforms have failed.
These allosteric inhibitors have been shown to be efficacious and well tolerated in animals, the company claimed.